Welcome to the BRAIN TUMORS 2016 - FROM BIOLOGY TO THERAPY Conference
June 27-29, 2016 • Warsaw, Poland
Venue: Nencki Institute of Experimental Biology, Pasteur 3 str.
New abstract submission deadline is June 8, 2016
Early registration deadline is April 30, 2016
It is my big pleasure and honor to invite You to participate in the "Brain Tumors Meeting 2016 - From Biology to Therapy", which will take place on June 27-29, 2016 in Warsaw, Poland. The conference is organized by the Nencki Institute of Experimental Biology, Institute of Psychiatry and Neurology, and Foundation of Clinical and Experimental Oncology. The conference will take place at the conference hall of the Neurobiology Center, Nencki Institute of Experimental Biology, 3 Pasteur str., Warsaw.
The main advantage of the conference is its high scientific quality, avoidance of parallel scientific sessions, enough planned time for discussion, specialized topics focused on basic and clinical research on brain tumor biology and therapy. During the Meeting the lectures will be presented by internationally recognized experts and will cover recent advances in pathobiology, immunology, diagnosis and therapy of brain tumors. Complex interactions between tumor cells, microenvironment and host immunity will be discussed. The conference provides unique opportunity for students and young investigators to present posters and be selected for short talks. Collegial environment will foster interdisciplinary cross-talks and spark new scientific collaborations.
See You in Warsaw
Prof. Bozena Kaminska
Chair of the Organizing Committee
|MONDAY, 27 June 2016|
|Origin of brain tumors and glioblastoma heterogeneity Chairs: Dolores Hambardzumyan, Bozena Kaminska|
Keynote lecture: Colin Watts (University of Cambridge, UK) - Surgical strategies to interrogate the genomics of glioblastoma.
Dominik Sturm (University Hospital Heidelberg and German Cancer Research Center, Germany) - Molecular characterization of CNS primitive neuroektodermal tumors
|11.10-11.50||Lene Uhrbom (University of Uppsala, Sweden) - A cell of origin–based strategy to decipher glioblastoma biology|
|11.50-12.30||Simone Niclou (Luxemburg Institute of Health, Luxemburg) - Resolving genetic and phenotypic heterogeneity in glioblastoma|
|12.30-13.10||Ben Deneen (Baylor College of Medicine, Houston, USA) - Identification of diverse astrocytic populations and their emergence during glioma induced seizures|
|13.10-14.00||Lunch break and sponsored lectures|
|Brain tumor therapy I Chairs: Zvi Cohen, Pawel Nauman|
|14.00-14.40||Zvi Cohen (Sheba Medical Center, Tel Ashomer, Israel) - Harnessing nanomedicine as a new approach for GBM treatment|
|14.40-15.20||Geoffrey Pilkington (University of Portsmouth, UK) - Re-purposed drugs for brain tumour|
|15.20-16.00||Joan Seoane (Valld’Hebron Institute of Oncology, Spain) - Glioblastoma microenvironment|
Susan Brandenburg (Charité - Universitätsmedizin Berlin, Germany) - In human GBM, the pro-angiogenic phenotype of microglia/macrophages depends on the infiltration rate of granulocytes
Roland E. Kälin (University Clinics, LMU Munich, Germany) - Apelin signaling controls glioblastoma neo-vascularization and growth
Dominika Pszczolkowska (Nencki Institute of Experimental Biology, Poland) - Tumor-derived osteopontin via its RGD motif is responsible for the protumorigenic reprogramming of glioma- infiltrating microglia/macrophages and glioma growth
|17.10-17.50||Rolf Bjerkvig (University of Bergen, Norway) - Identifying new drugs for primary and secondary brain tumours using cMap|
|TUESDAY, 28 June 2016|
|Signaling in brain tumors Chairs: Lene Uhrbom, Aleksandra Ellert-Miklaszewska|
Keynote lecture: Daniel J. Brat (Winship Cancer Institute of Emory University, Atlanta, USA) - A contemporary molecular view of diffuse gliomas with implications for diagnosis
Ksenya Shchors (Swiss Federal Institute of Technology, Switzerland) - Combinatorial therapy design in glioblastoma models
Etty (Tika) Benveniste (University of Alabama, Birmingham, USA) - Role of CK2 in GBM and autoimmunity
|11.40-12.20||Bozena Kaminska (Nencki Institute, Warsaw, Poland) - Glioma-derived osteopontin/SPP1 supports glioma stem-like cells and shapes anti-tumor responses|
|Glioma immunology and immunotherapy Chairs: Tika Benveniste, Katarzyna Kotulska|
Duane Mitchell (University of Florida, USA) - Cellular immunotherapy targeting malignant gliomas
|13.50-14.30||Dolores Hambardzumyan (Emory University School of Medicine, Atlanta, USA) - The role of pro-inflammatory chemokine network in gliomagenesis|
|14.30-15.10||Christel Herold-Mende (University Hospital Heidelberg, Germany) - Immunological changes during tumor progression from primary to recurrent glioblastoma|
|15.40-16.20||Michael Platten (University Hospital Heidelberg and German Cancer Research Center, Germany) - Targeting IDH1R132H for glioma immunotherapy|
|16.20-17.00||Gaetano Finocchiaro (IRCCS Foundation "C. Besta" Neurological Institute, Milan, Italy) - Glioblastoma immunotherapy|
|17.00-19.00||Poster session (wine and cheese by the posters)|
|20.00-22.00||Gala Dinner (by invitation)|
|WEDNESDAY, 29 June 2016|
|Glioma signaling and biology Chairs: Frank AE Kruyt, Cristina Limatola|
Keynote lecture: Katarzyna Kotulska (The Children’s Memorial Health Institute, Poland) - mTOR inhibitors in tuberous sclerosis: from brain tumor treatment to the control of systemic disease
|09.40-10.20||Monika Hegi (University Hospital Lausanne, Switzerland) - Epigenetic Deregulation in Glioma, Biomarkers and New Opportunities|
|10.20-11.00||François Vallette (University of Nantes, France) - Identification of a drug tolerant stage during the acquisition of TMZ resistance in glioma|
Steven Rosenfeld (Cleveland Clinic, USA) - Molecular motors are drivers of proliferation and invasion in glioblastoma
|12.10-12.50||Frank AE Kruyt (University of Groningen, Netherlands) - Differentiation and invasion in glioblastoma|
|12.50-13.30||Cristina Limatola (Sapienza University, Rome, Italy) - Environmental and pharmacological tools to reprogram microglia/macrophages infiltrating brain tumor|
|13.30-14.10||Jacek Jaworski (International Institute of Molecular and Cellular Biology, Warsaw, Poland) - Tuberous Sclerosis Complex neuropathology requires glutamate-cysteine ligase|
|14.40...||Guided tour: Warsaw sightseeing|
- Etty (Tika) Benveniste, University of Alabama, USA
- Karin Forsberg- Nilsson, Uppsala University, Sweden
- Dolores Hambardzumyan, Emory University, USA
- Bozena Kaminska, Nencki Institute, Poland
The Local Organizing Committee
- Aleksandra Ellert-Miklaszewska, Nencki Institute
- Anna Gieryng, Nencki Institute
- Bozena Kaminska, Nencki Institute
- Marta Maleszewska, Nencki Institute
- Pawel Nauman, Institute of Psychiatry and Neurology
- Cezary Szczylik, Central Military Hospital
- Pawel Wisniewski, Helix Polska
Registration Deadlines and Pricing
You may register for this meeting on this web site until May 30, 2016.
The Registration Fee includes: admission to speaker talks and poster displays, abstract book, coffee breaks service, refreshments at poster sessions, Welcome Reception
The Registration Fee is €200 on and before April 30, 2016.
After April 30, 2016 or onsite, the Registration Fee is €260.
All students are offered a special registration rate.
To qualify for the Student Discount, you must be enrolled in an undergraduate, M.S., Ph.D. or M.D. program.
The Student Registration Fee is €50.
The Registration Fee is €300 on and before April 30, 2016.
After April 30, 2016 or onsite, the Registration Fee is €400.
By bank transfer to the following account:
ACCOUNT HOLDER: NENCKI INSTITUTE OF EXPERIMENTAL BIOLOGY
BANK DETAILS: BGK, AL. JEROZOLIMSKIE 7 W WARSZAWIE
ACCOUNT NO IBAN: PL95 1130 1017 0013 4337 2320 0008
SWIFT CODE: GOSKPLPW
Please do not forget to indicate "Brain Tumors 2016" and your name and affiliation on the money transfer form.
More About Warsaw